Compare Mongodb Inc (MDB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Recursion Pharmaceuticals Inc — how do they compare? Mongodb Inc trades at $375.46 (market cap $29.24B), while Recursion Pharmaceuticals Inc trades at $3.96 (market cap $2.14B). The key difference: Mongodb Inc is far larger — about 13.7× Recursion Pharmaceuticals Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 45 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| MDB | RXRX | |
|---|---|---|
Market Cap | $29.24B | $2.14B |
Volume | 1,304,995 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $472.29 | $6.79 |
52-Week Low | $225.95 | $2.84 |
Typical Hold Time | 45 Days | 22 Days |
Enterprise Value | $26.86B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $363.03, up 0.64% today, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds with a high P/E of 511.31 and negative net income, though revenue growth remains strong, reaching $2.01B in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.
Outlook: Long-term growth potential exists with raised AI-focused targets, but high valuation and profitability challenges pose risks. Analyst consensus is bullish with an $456.76 price target, yet technical indicators and cash flow volatility warrant caution for near-term volatility.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
